THRβ-Selective Agonist Compound for Reduced Cardiac Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thyroid hormone receptor (THR) agonists cause side effects such as heart issues and thyroid axis inhibition, limiting their effectiveness in treating metabolic disorders like non-alcoholic steatohepatitis (NASH) and NAFLD, despite their potential benefits in regulating lipid metabolism.
Innovation Solution
Development of a compound represented by Formula (I) and its pharmaceutically acceptable salts, which exhibit improved selectivity towards THRβ receptors, maintaining agonistic activity while reducing thyroid axis inhibition, and possessing desirable pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormone receptor agonists are used to treat metabolic disorders, then lipid metabolism regulation is improved, but heart-related side effects occur
Solution Approach 1:
The patent segments the thyroid hormone receptor into two distinct subtypes (THRα and THRβ) and develops compounds that selectively target THRβ. This segmentation allows the drug to activate THRβ for lipid metabolism regulation while avoiding THRα activation that causes heart-related side effects, thus resolving the contradiction between therapeutic efficacy and safety
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (Formula I and Formula II) that have differentiated binding properties - they possess high affinity for THRβ receptors while having minimal affinity for THRα receptors. This localized specificity in receptor interaction enables selective activation of desired pathways without triggering adverse effects in cardiac tissues
2Object-affected harmful factors
If selective THRβ agonists are used to avoid heart side effects, then cardiac safety is improved, but thyroid axis inhibition occurs
Solution Approach 1:
The patent employs partial action by designing THRβ-selective agonists that provide sufficient activation of THRβ to achieve lipid metabolism benefits without excessive activation that would suppress the thyroid axis. The compounds are optimized to activate THRβ at therapeutic doses while maintaining thyroid hormone homeostasis, thus avoiding both heart side effects and thyroid axis inhibition
3Reliability
If natural thyroid hormone is used to regulate serum cholesterol, then cholesterol levels are improved, but multiple side effects occur
Solution Approach 1:
The patent extracts the beneficial cholesterol-lowering function from natural thyroid hormone by selectively targeting THRβ, which is primarily expressed in the liver and involved in lipid metabolism. By taking out this specific function and isolating it through THRβ-selective agonism, the patent achieves cholesterol regulation without the multiple side effects (tachycardia, arrhythmia, heart failure, osteoporosis) associated with full thyroid hormone activation of both THRα and THRβ
Data Source
AI summary
The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.